Essential Partners’s ArriVent BioPharma AVBP Stock Holding History

Essential Partners’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$303	Hold	10	–	–	﹤0.01%	2520
2026 Q2	$347	Buy	10 +2	+25%	+$59	﹤0.01%	2543
2026 Q1	$185	Buy	8 +7	+700%	+$158	﹤0.01%	2626
2025 Q4	$20	Hold	1	–	–	﹤0.01%	2720
2025 Q3	$18	Buy	+1	New	+$20	﹤0.01%	2642

Other funds holding AVBP

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners's AVBP Position: Q3 2026 in Review

Essential Partners held its ArriVent BioPharma (AVBP) position steady in Q3 2026 at 10 shares worth $303. The position accounts for ﹤0.01% of the portfolio, ranked #2520.

Essential Partners first reported a position in AVBP in Q3 2025 and has held it in 5 quarters since. The position peaked at $347 in Q2 2026. 7 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

Essential Partners held 10 shares of ArriVent BioPharma worth $303 as of Q3 2026.
Essential Partners left its ArriVent BioPharma share count unchanged in Q3 2026.
ArriVent BioPharma made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2520 holding.
Essential Partners first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 5 quarters since.
Essential Partners's ArriVent BioPharma position peaked at $347 in Q2 2026.
7 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.